Order Entry
Canada
ContactUsLinkComponent
ENDONEXT™ EndoZyme® II – Recombinant Factor C (rFC) Endotoxin Detection Assay, BioVendor
ENDONEXT™ EndoZyme® II – Recombinant Factor C (rFC) Endotoxin Detection Assay, BioVendor
Catalog # 103501-438
Supplier:  BioVendor
CAS Number:  
ENDONEXT™ EndoZyme® II – Recombinant Factor C (rFC) Endotoxin Detection Assay, BioVendor
Catalog # 103501-438
Supplier:  BioVendor
Supplier Number:  890030
CAS Number:  

Some Products May Appear Restricted

To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.

If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/ca/en/login/register)

 

If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation;  additional documentation will be requested for these items prior to shipment. 

Specifications

  • Description:
    ENDONEXT™ EndoZyme® rFC endotoxin detection kit
  • Size:
    1 kit
  • Storage conditions:
    Unopened kits are stable at 2…8 °C until the expiry date printed on the label
  • Cat. no.:
    103501-438
  • No. of Tests:
    192

Specifications

About this item

The ENDONEXT™ EndoZyme® II assay is the enhanced second generation of EndoZyme®, based on recombinant Factor C (rFC), the synthetic analogue to the native endotoxin-specific principal receptor in the limulus amebocyte lysate (LAL) cascade.

  • Horseshoe crab-free method relying on sustainable resources
  • State-of-the-art sensitivity (0.005 EU/ml) and assay range
  • Endotoxin-specific, no false-positive results from β-glucans
  • Excellent lot-to-lot reproducibility
  • Stable liquid reagents enabling flexibility in use
  • Follows BET methodology and validated according to the same criteria as conventional methods
  • Accepted by the FDA and included in the European Pharmacopoeia chapter 5.1.10 since 2016